Department of Clinical Pharmaceutical Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan.
Department of Neurosurgery, Kitasato University School of Medicine, Sagamihara, Japan.
Cancer Sci. 2020 Jun;111(6):2041-2051. doi: 10.1111/cas.14399. Epub 2020 Apr 30.
Glioblastoma multiforme (GBM), a lethal brain tumor developing in the white matter of the adult brain, contains a small population of GBM stem cells (GSCs), which potentially cause chemotherapeutic resistance and tumor recurrence. However, the mechanisms underlying the pathogenesis and maintenance of GSCs remain largely unknown. A recent study reported that incorporation of ribosomes and ribosomal proteins into somatic cells promoted lineage trans-differentiation toward multipotency. This study aimed to investigate the mechanism underlying stemness acquisition in GBM cells by focusing on 40S ribosomal protein S6 (RPS6). RPS6 was significantly upregulated in high-grade glioma and localized at perivascular, perinecrotic, and border niches in GBM tissues. siRNA-mediated RPS6 knock-down significantly suppressed the characteristics of GSCs, including their tumorsphere potential and GSC marker expression; STAT3 was downregulated in GBM cells. RPS6 overexpression enhanced the tumorsphere potential of GSCs and these effects were attenuated by STAT3 inhibitor (AG490). Moreover, RPS6 expression was significantly correlated with SOX2 expression in different glioma grades. Immunohistochemistry data herein indicated that RPS6 was predominant in GSC niches, concurrent with the data from IVY GAP databases. Furthermore, RPS6 and other ribosomal proteins were upregulated in GSC-predominant areas in this database. The present results indicate that, in GSC niches, ribosomal proteins play crucial roles in the development and maintenance of GSCs and are clinically associated with chemoradioresistance and GBM recurrence.
多形性胶质母细胞瘤(GBM)是一种在成人脑白质中发展的致命脑肿瘤,其中包含一小部分 GBM 干细胞(GSCs),这些细胞可能导致化疗耐药和肿瘤复发。然而,GSCs 发生和维持的机制在很大程度上仍然未知。最近的一项研究报告称,核糖体和核糖体蛋白整合到体细胞中会促进谱系向多能性的转化。本研究旨在通过聚焦 40S 核糖体蛋白 S6(RPS6)来研究 GBM 细胞中获得干性的机制。RPS6 在高级别神经胶质瘤中显著上调,并定位于 GBM 组织中的血管周围、坏死周围和边界龛中。siRNA 介导的 RPS6 敲低显著抑制了 GSCs 的特征,包括其肿瘤球形成能力和 GSC 标志物表达;GBM 细胞中的 STAT3 下调。RPS6 过表达增强了 GSCs 的肿瘤球形成能力,而 STAT3 抑制剂(AG490)则减弱了这些效应。此外,RPS6 的表达与不同胶质瘤分级中的 SOX2 表达显著相关。免疫组织化学数据表明,RPS6 主要存在于 GSC 龛中,与 IVY GAP 数据库中的数据一致。此外,在该数据库中,RPS6 和其他核糖体蛋白在 GSC 优势区域上调。这些结果表明,在 GSC 龛中,核糖体蛋白在 GSCs 的发育和维持中发挥着关键作用,并且与化学放射耐药性和 GBM 复发具有临床相关性。